Last search for anti hypertensives
Reading File
Finding Sources
Searching PubMed
"antihypertensive" AND "hypertension treatment"
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive data from Goodman & Gilman's and Family Medicine textbooks. Here is the full, organized reference on antihypertensives:
Antihypertensive Drugs - Comprehensive Summary
Definition & Goals
Hypertension is defined as:
- USA (AHA/ACC): BP ≥ 130/80 mmHg
- Europe (ESC): BP ≥ 140/90 mmHg
The primary goal of antihypertensive therapy is blood pressure lowering per se - evidence from large prospective trials shows no major outcome difference between drug classes when BP is equally controlled.
First-Line Drug Classes
The four preferred first-line classes (no compelling indications) are:
| Class | Key Examples |
|---|---|
| ACE Inhibitors | Captopril, Enalapril, Lisinopril, Ramipril, Perindopril |
| ARBs | Valsartan, Losartan, Candesartan, Olmesartan, Telmisartan |
| Calcium Channel Blockers (CCBs) | Amlodipine, Nifedipine (ER), Diltiazem, Verapamil |
| Thiazide/Thiazide-like Diuretics | Hydrochlorothiazide, Chlorthalidone, Indapamide |
Drug Classes: Mechanisms & Key Points
1. Thiazide Diuretics
- MOA: Block the NaCl cotransporter (SLC12A3) in the distal convoluted tubule → initial decrease in extracellular volume → long-term decrease in peripheral vascular resistance (indirect, via negative Na+ balance)
- Examples: Hydrochlorothiazide, chlorthalidone, indapamide
- Adverse effects: Hypokalemia, hyperglycemia, hyperuricemia, hyponatremia
- Note: Lose efficacy in renal insufficiency (GFR < 30); loop diuretics preferred then
2. Loop Diuretics
- Examples: Furosemide (20-80 mg, twice daily), Bumetanide, Torsemide, Ethacrynic acid
- Use: Volume overload, renal insufficiency, resistant hypertension
- SE: Hypokalemia, ototoxicity (ethacrynic acid - only non-sulfonamide)
3. Potassium-Sparing Diuretics / MRA
- Spironolactone (12.5-100 mg) - aldosterone antagonist, SE: gynecomastia
- Eplerenone (25-50 mg) - more selective, less gynecomastia
- Amiloride, Triamterene - ENaC blockers; SE: hyperkalemia
- Use: Resistant hypertension (4th-line add-on), heart failure, Conn syndrome
4. Beta-Blockers (β-Blockers)
- MOA: Reduce cardiac output (decrease HR and contractility); reduce renin release; central sympatholytic effects
- Cardioselective: Atenolol, Bisoprolol, Metoprolol succinate (preferred), Nebivolol
- Non-selective: Propranolol, Nadolol, Timolol
- Mixed α/β: Carvedilol, Labetalol
- Preferred when: Post-MI, ischemic heart disease, atrial fibrillation, HFrEF, younger patients with high sympathetic drive
- Contraindications/Caution: Asthma/COPD, decompensated heart failure, AV block
- Note: Once-daily dosing preferred (extended-release metoprolol succinate)
5. ACE Inhibitors
- MOA: Inhibit conversion of Angiotensin I → Angiotensin II → decreased vasoconstriction, decreased aldosterone, reduced afterload/preload
- Examples: Captopril*, Enalapril, Lisinopril, Ramipril, Perindopril, Benazepril, Fosinopril
- Special benefits: Diabetic nephropathy (slow progression of glomerulopathy), chronic kidney disease, proteinuria, post-MI, HFrEF
- Adverse effects: Dry cough (bradykinin accumulation), angioedema (contraindicated if prior angioedema), hyperkalemia, teratogenic (avoid in pregnancy)
- *Short half-life of captopril makes it unsuitable for chronic once-daily use
6. Angiotensin Receptor Blockers (ARBs)
- MOA: Selective competitive antagonism at AT1 receptor → same downstream effects as ACEi but without bradykinin accumulation
- Examples: Valsartan, Losartan, Candesartan, Olmesartan, Telmisartan, Irbesartan, Azilsartan
- Advantages over ACEi: No dry cough, lower risk of angioedema
- Uses: Same as ACEi; also atrial fibrillation prevention, portal hypertension, stroke prevention
- Adverse effects: Hyperkalemia; teratogenic (contraindicated in pregnancy); do NOT combine with ACEi (increased adverse effects without added benefit)
7. Calcium Channel Blockers (CCBs)
- Dihydropyridines (arterial selective): Amlodipine, Nifedipine ER, Felodipine, Clevidipine (IV, ultra-short)
- Preferred for: Isolated systolic hypertension, elderly, asymptomatic atherosclerosis, angina
- SE: Peripheral edema, reflex tachycardia
- Non-dihydropyridines (cardiac): Diltiazem (benzothiazepine), Verapamil (phenylalkylamine)
- Rate control in AF, angina
- SE: Bradycardia, constipation (verapamil), AV block; contraindicated with β-blockers (risk of complete heart block)
8. Alpha-1 Blockers
- MOA: Block α1 adrenergic receptors → arteriolar and venous dilation
- Examples: Prazosin (1-10 mg, twice daily), Terazosin (1-20 mg), Doxazosin (2-16 mg)
- Favorable metabolic effects: Reduce LDL/triglycerides, raise HDL
- Not recommended as monotherapy (ALLHAT trial showed inferior outcomes)
- Preferred add-on in: BPH with hypertension
- SE: First-dose orthostatic hypotension, salt/water retention
9. Central Alpha-2 Agonists
- MOA: Stimulate central α2 receptors → reduce sympathetic outflow
- Clonidine (0.1-0.8 mg, 2-3x daily; also TTS patch): Sedation, dry mouth, rebound hypertension on withdrawal
- Methyldopa (250-500 mg, twice daily): Drug of choice in pregnancy; SE: hepatic disorders, autoimmune hemolytic anemia
- Guanfacine - less withdrawal risk than clonidine
- Moxonidine - selective I1 imidazoline receptor agonist
10. Direct Vasodilators
- Hydralazine - arterial vasodilator; SE: reflex tachycardia, lupus-like syndrome (high dose); used in pregnancy (IV)
- Minoxidil - potent arterial vasodilator (K+ channel opener); reserved for resistant hypertension; causes hirsutism, fluid retention
- Sodium nitroprusside - arterial + venous; IV only; hypertensive emergencies; SE: cyanide toxicity
- Diazoxide, Fenoldopam (DA1 agonist) - IV use for hypertensive crisis
11. Newer Agents
- Aldosterone synthase inhibitors (e.g., lorundrostat, baxdrostat) - emerging class; meta-analysis (2025, PMID 39886765) shows significant BP reduction with acceptable safety profile
- Low-dose triple single-pill combinations (e.g., telmisartan + amlodipine + chlorthalidone) - systematic review (2025, PMID 40488970) supports efficacy and safety in LMICs
Drug Selection by Comorbidity
| Comorbidity | Preferred Agents |
|---|---|
| Diabetes mellitus | ACEi, ARB, CCB, thiazide |
| Diabetes + proteinuria | ACEi, ARB |
| Chronic kidney disease / proteinuria | ACEi, ARB |
| Post-MI | ACEi, ARB, BB |
| Coronary artery disease / Angina | BB, CCB, ACEi, ARB |
| Heart failure (HFrEF) | ACEi, ARB, BB, diuretics, MRA |
| Atrial fibrillation (rate control) | BB, non-DHP CCBs |
| Atrial fibrillation (prevention) | ACEi, ARB, BB |
| Stroke prevention | ACEi, ARB, diuretics |
| Left ventricular hypertrophy | ACEi, ARB, CCB |
| Isolated systolic hypertension | ACEi, ARB, CCB, diuretics |
| Metabolic syndrome | ACEi, ARB, CCB |
| BPH | α1 blockers |
| Pregnancy | Methyldopa, Labetalol, Hydralazine, Nifedipine |
| Pheochromocytoma | Phenoxybenzamine (irreversible α-blocker) |
| Peripheral artery disease | ACEi, CCB |
| Aortic aneurysm | BB |
| Asymptomatic atherosclerosis | CCB |
| Renal insufficiency | ACEi, ARB (+ loop diuretics if GFR low) |
Combination Therapy Principles
- Preferred combinations: ACEi or ARB + CCB + thiazide diuretic (as single-pill if possible)
- BB added as 4th drug in resistant hypertension or when specific indication exists
- Avoid combining: ACEi + ARB (dual RAS blockade), BB + non-DHP CCB (risk of complete heart block)
- Trough-to-peak ratio > 50% required for 24-hour BP control (guides once-daily dosing)
Resistant Hypertension
- Defined as BP above goal despite 3 drugs (including a diuretic) at maximum tolerated doses
- Consider spironolactone as 4th agent
- Rule out secondary causes: primary hyperaldosteronism, renal artery stenosis, sleep apnea, medication non-adherence
Special Populations
| Population | Key Considerations |
|---|---|
| Elderly | Thiazides first-step; CCBs safe; orthostatic hypotension risk; avoid high-dose thiazides |
| Pregnancy | Methyldopa, labetalol, nifedipine ER; ACEi/ARBs contraindicated |
| Breastfeeding | Specific agents safe - consult Brenner & Rector's guidelines |
| Renal insufficiency | Loop diuretics > thiazides; ACEi/ARBs preferred but monitor K+/creatinine |
| African Americans | Thiazides and CCBs more effective; ACEi/ARBs less effective as monotherapy |
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics; Katzung's Basic & Clinical Pharmacology, 16e; Textbook of Family Medicine, 9e; Brenner & Rector's The Kidney
Recent evidence update:
- Aldosterone synthase inhibitors show promising BP reduction (Meta-analysis, 2025 - PMID 39886765)
- Low-dose triple single-pill combinations are effective and safe in LMICs (Systematic review, 2025 - PMID 40488970)
- Network meta-analysis of 6 ARBs (2024, PMID 38861046) found broadly comparable efficacy across the ARB class
Make a chart of different antihypertensives used in different comorboditis with drug dose and also include side effects and contraindications make chart in colourful design
Reading File
Reading File
Reading File
Reading File
Running Command
Running Command
Writing File
Running Command
Running Command
Your colourful antihypertensive chart is ready!
Antihypertensives Drug Chart
Presentation · PPTX
Here is what is inside the 11-slide PPTX (403 KB, LAYOUT_WIDE 13.3×7.5"):
| Slide | Content |
|---|---|
| 1 | Title slide - dark navy with teal/coral accents and pill motifs |
| 2 | Thiazide & Thiazide-like Diuretics (sky blue theme) - HCTZ, Chlorthalidone, Indapamide |
| 3 | Loop Diuretics (indigo) - Furosemide, Bumetanide, Torsemide |
| 4 | K-Sparing Diuretics / MRA (teal) - Spironolactone, Eplerenone, Amiloride |
| 5 | Beta-Blockers (coral/red) - Metoprolol, Bisoprolol, Carvedilol, Labetalol |
| 6 | ACE Inhibitors (green) - Ramipril, Lisinopril, Enalapril/Perindopril |
| 7 | ARBs (gold) - Valsartan, Losartan, Telmisartan/Olmesartan |
| 8 | Calcium Channel Blockers (violet) - Amlodipine, Nifedipine ER, Diltiazem, Verapamil |
| 9 | Alpha-blockers + Central Agonists (orange) - Doxazosin, Clonidine, Methyldopa |
| 10 | Direct Vasodilators (purple) - Hydralazine, Minoxidil, Nitroprusside |
| 11 | Comorbidity Quick Reference Table - all 12 comorbidities with preferred drugs, avoid list, and key dose notes |
| 12 | Key Prescribing Principles - 7 rules (dark slide with gold/colour-coded numbered blocks) |
Each drug slide has 5 colour-coded columns: Drug/Examples | Dose Range | Comorbidities (Preferred) | Side Effects | Contraindications, with alternating row shading and a colour dot indicator per class.
Create a summary PDF quick-reference card for clinical pocket use
Reading File
Writing File
Running Command
Running Command
Your pocket card is ready:
Antihypertensives Pocket Card
PDF Document · PDF
Here is what is inside the A5 landscape, print-ready PDF:
Layout: Navy header bar + gold accent strip on every page, branded footer, page numbers.
| Page | Content |
|---|---|
| 1-3 | Drug-class tables - one colour-coded block per class (10 classes total). Each row shows: Drug name |
| 4 | Comorbidity Quick-Look Table - 12 conditions (post-MI, HF, diabetes, CKD, stroke, pregnancy, asthma, HTN emergency, AF, BPH, phaeochromocytoma, resistant HTN) with preferred agents, what to avoid (in red), and key dose notes |
| 5 | Key Prescribing Rules - 8 rules with colour-coded labels (green = ok, red = danger, gold = warning) covering first-line combinations, when to add β-blockers, dangerous combos to avoid, pregnancy rules, and resistant HTN management |
| 5 (cont.) | BP Target Mini-Table - AHA/ACC vs ESC targets for 6 populations side-by-side |
This is a shared conversation. Sign in to Orris to start your own chat.